Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement

Simple item page
dc.contributor.authorKlimek, L
dc.contributor.authorJutel, M
dc.contributor.authorAkdis, C
dc.contributor.authorBousquet, J
dc.contributor.authorAkdis, M
dc.contributor.authorBachert, C
dc.contributor.authorAgache, I
dc.contributor.authorAnsotegui, I
dc.contributor.authorBedbrook, A
dc.contributor.authorBosnic-Anticevich, S
dc.contributor.authorCanonica, GW
dc.contributor.authorChivato, T
dc.contributor.authorCruz, AA
dc.contributor.authorCzarlewski, W
dc.contributor.authorDel Giacco, S
dc.contributor.authorDu, H
dc.contributor.authorFonseca, JA
dc.contributor.authorGao, YD
dc.contributor.authorHaahtela, T
dc.contributor.authorHoffmann-Sommergruber, K
dc.contributor.authorIvancevich, JC
dc.contributor.authorKhaltaev, N
dc.contributor.authorKnol, EF
dc.contributor.authorKuna, P
dc.contributor.authorLarenas-Linnemann, D
dc.contributor.authorMelén, E
dc.contributor.authorMullol, J
dc.contributor.authorNaclerio, R
dc.contributor.authorOhta, K
dc.contributor.authorOkamoto, Y
dc.contributor.authorO'Mahony, L
dc.contributor.authorOnorato, GL
dc.contributor.authorPapadopoulos, NG
dc.contributor.authorPawankar, R
dc.contributor.authorPfaar, O
dc.contributor.authorSamolinski, B
dc.contributor.authorSchwarze, J
dc.contributor.authorToppila-Salmi, S
dc.contributor.authorShamji, MH
dc.contributor.authorVentura, MT
dc.contributor.authorValiulis, A
dc.contributor.authorYorgancioglu, A
dc.contributor.authorMatricardi, P
dc.contributor.authorZuberbier, T
dc.date.accessioned2024-07-18T12:08:52Z
dc.date.available2024-07-18T12:08:52Z
dc.description.abstractThe current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
dc.identifier.issn0105-4538
dc.identifier.other1398-9995
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11073
dc.language.isoEnglish
dc.publisherWILEY
dc.subjectVENOM ALLERGY
dc.subjectASTHMA
dc.subjectMECHANISMS
dc.subjectVACCINES
dc.titleHandling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu